Clinical Trial Update: Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating risperidone augmentation in partial responders to SRIs for treatment-resistant depression was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Risperdal (risperidone)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Treatment Resistant Depression | Phase 4 | Status: WITHDRAWN